These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34676158)

  • 41. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
    Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
    Front Oncol; 2021; 11():705929. PubMed ID: 34722250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.
    Xie ZC; Wu HY; Ma FC; Dang YW; Peng ZG; Zhou HF; Chen G
    Am J Transl Res; 2019; 11(7):4010-4028. PubMed ID: 31396315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma.
    Wu Z; Liu J; Sun R; Chen D; Wang K; Cao C; Xu X
    Front Genet; 2019; 10():1333. PubMed ID: 32063918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic role of alternative splicing events in head and neck squamous cell carcinoma.
    Ding Y; Feng G; Yang M
    Cancer Cell Int; 2020; 20():168. PubMed ID: 32467664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternative splicing event associated with immunological features in bladder cancer.
    Yu X; Luo B; Lin J; Zhu Y
    Front Oncol; 2022; 12():966088. PubMed ID: 36686818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.
    Yu J; Mao W; Xu B; Chen M
    Cancer Med; 2021 Apr; 10(7):2359-2369. PubMed ID: 33650306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic analysis of survival-associated alternative splicing signatures in clear cell renal cell carcinoma.
    Chen T; Zheng W; Chen J; Lin S; Zou Z; Li X; Tan Z
    J Cell Biochem; 2020 Oct; 121(10):4074-4084. PubMed ID: 31886566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma.
    Huang R; Yan G; Sun H; Zhang J; Song D; Kong R; Yan P; Hu P; Xie A; Wang S; Zhuang J; Yin H; Meng T; Huang Z
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32627826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of an alternative splicing signature as an independent factor in colon cancer.
    Chen H; Luo J; Guo J
    BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
    Zhang D; Duan Y; Wang Z; Lin J
    Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer.
    Yu M; Hong W; Ruan S; Guan R; Tu L; Huang B; Hou B; Jian Z; Ma L; Jin H
    Front Oncol; 2019; 9():773. PubMed ID: 31552163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An alternative splicing signature model for predicting hepatocellular carcinoma-specific survival.
    Dong S; Lu LJ
    J Gastrointest Oncol; 2020 Oct; 11(5):1054-1064. PubMed ID: 33209497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
    Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
    Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer.
    Zong Z; Li H; Yi C; Ying H; Zhu Z; Wang H
    Front Oncol; 2018; 8():537. PubMed ID: 30524964
    [No Abstract]   [Full Text] [Related]  

  • 55. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
    Xiong C; Wang G; Bai D
    Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer.
    Shi JY; Bi YY; Yu BF; Wang QF; Teng D; Wu DN
    Front Oncol; 2021; 11():583547. PubMed ID: 33996533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic alternative splicing regulatory network of splicing events in acute myeloid leukemia patients based on SpliceSeq data from 136 cases.
    Xie ZC; Gao L; Chen G; Ma J; Yang LH; He RQ; Li MW; Cai KT; Li TT; Peng ZG
    Neoplasma; 2020 May; 67(3):623-635. PubMed ID: 32039631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
    Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
    Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
    Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
    Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma.
    Cao R; Zhang J; Jiang L; Wang Y; Ren X; Cheng B; Xia J
    Front Oncol; 2020; 10():1740. PubMed ID: 32984057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.